BioCentury | Feb 18, 2013
Clinical News

CP024: Phase I data

...a Phase I trial in 7 healthy volunteers showing that 2-6 mg doses of intranasal CP024...
...an infusion of octreotide "strongly" induced the production of insulin-like growth factor-1 ( IGF-1 ). CP024...
...partner before starting Phase II/III trials of CP024. Critical Pharmaceuticals Ltd. , Nottingham, U.K. Product: CP024...
BioCentury | Sep 12, 2011
Clinical News

CP024: Interim Phase I data

...Interim data from a Phase I trial in healthy volunteers showed that intranasal CP024 produced insulin-like...
...IGF-I) levels comparable to that of a subcutaneous injection of an undisclosed marketed hGH product. CP024...
...Phase Ib trial of CP024 early next year. Critical Pharmaceuticals Ltd. , Nottingham, U.K. Product: CP024...
BioCentury | Mar 14, 2011
Clinical News

Critical Pharmaceuticals preclinical data

...In rats, repeated intranasal administration of CP024 over 14 days was tolerable with no adverse effects...
...with its CriticalSorb nasal delivery technology next quarter. Critical Pharmaceuticals Ltd. , Nottingham, U.K. Product: CP024...
Items per page:
1 - 3 of 3